417 related articles for article (PubMed ID: 33960173)
1. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
[TBL] [Abstract][Full Text] [Related]
2. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
3. Lodenafil.
Alshehri YM; Al-Majed AA; Attwa MW; Bakheit AH
Profiles Drug Subst Excip Relat Methodol; 2022; 47():113-147. PubMed ID: 35396013
[TBL] [Abstract][Full Text] [Related]
4. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
Lombardo R; Tema G; De Nunzio C
Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
9. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
10. Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
Sheweita SA; Wally M; Hassan M
Oxid Med Cell Longev; 2016; 2016():4970906. PubMed ID: 27800121
[TBL] [Abstract][Full Text] [Related]
11. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
12. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
[TBL] [Abstract][Full Text] [Related]
13. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
16. PDE-5 inhibitors: clinical points.
Doumas M; Lazaridis A; Katsiki N; Athyros V
Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
Madeira CR; Tonin FS; Fachi MM; Borba HH; Ferreira VL; Leonart LP; Bonetti AF; Moritz RP; Trindade ACLB; Gonçalves AG; Fernandez-Llimos F; Pontarolo R
World J Urol; 2021 Mar; 39(3):953-962. PubMed ID: 32388784
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Kuthe A
Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
[TBL] [Abstract][Full Text] [Related]
20. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]